» Articles » PMID: 35526001

Recommendations from the IRDiRC Working Group on Methodologies to Assess the Impact of Diagnoses and Therapies on Rare Disease Patients

Overview
Publisher Biomed Central
Specialty General Medicine
Date 2022 May 7
PMID 35526001
Authors
Affiliations
Soon will be listed here.
Abstract

Rare disease patients face many challenges including diagnostic delay, misdiagnosis and lack of therapies. However, early access to diagnosis and therapies can modify the management and the progression of diseases, which in return positively impacts patients, families and health care systems. The International Rare Diseases Research Consortium set up the multi-stakeholder Working Group on developing methodologies to assess the impact of diagnoses and therapies on rare disease patients. Using the patients' journey on the diagnostic paradigm, the Working Group characterized a set of metrics, tools and needs required for appropriate data collection and establishment of a framework of methodologies to analyze the socio-economic burden of rare diseases on patients, families and health care systems. These recommendations are intended to facilitate the development of methodologies and to better assess the societal impact of rare diseases.

Citing Articles

Capturing Real-World Rare Disease Patient Journeys: Are Current Methodologies Sufficient for Informed Healthcare Decisions?.

Cribbs K, Blackmore L, Banks A, Kim D, Lahue B J Eval Clin Pract. 2025; 31(1):e70010.

PMID: 39960234 PMC: 11831961. DOI: 10.1111/jep.70010.


The Enigma That Is ROHHAD Syndrome: Challenges and Future Strategies.

Hawton K, Giri D, Crowne E, Greenwood R, Hamilton-Shield J Brain Sci. 2024; 14(11).

PMID: 39595809 PMC: 11591771. DOI: 10.3390/brainsci14111046.


Medical Genetics for the Undiagnosed and Rare Patient: "Chasing Zebras".

Sisco K, Oliva M Mo Med. 2024; 121(4):284-288.

PMID: 39575078 PMC: 11578571.


Objectivizing issues in the diagnosis of complex rare diseases: lessons learned from testing existing diagnosis support systems on ciliopathies.

Faviez C, Chen X, Garcelon N, Zaidan M, Billot K, Petzold F BMC Med Inform Decis Mak. 2024; 24(1):134.

PMID: 38789985 PMC: 11127295. DOI: 10.1186/s12911-024-02538-8.


An algorithm to identify patients aged 0-3 with rare genetic disorders.

Webb B, Lau L, Tsevdos D, Shewcraft R, Corrigan D, Shi L Orphanet J Rare Dis. 2024; 19(1):183.

PMID: 38698482 PMC: 11064409. DOI: 10.1186/s13023-024-03188-9.


References
1.
Michaels-Igbokwe C, McInnes B, MacDonald K, Currie G, Omar F, Shewchuk B . (Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta, Canada. Genet Med. 2020; 23(2):272-279. DOI: 10.1038/s41436-020-00975-0. View

2.
Pollard S, Weymann D, Dunne J, Mayanloo F, Buckell J, Buchanan J . Toward the diagnosis of rare childhood genetic diseases: what do parents value most?. Eur J Hum Genet. 2021; 29(10):1491-1501. PMC: 8484431. DOI: 10.1038/s41431-021-00882-1. View

3.
Cannizzo S, Lorenzoni V, Palla I, Pirri S, Trieste L, Triulzi I . Rare diseases under different levels of economic analysis: current activities, challenges and perspectives. RMD Open. 2018; 4(Suppl 1):e000794. PMC: 6241967. DOI: 10.1136/rmdopen-2018-000794. View

4.
Tisdale A, Cutillo C, Nathan R, Russo P, Laraway B, Haendel M . The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021; 16(1):429. PMC: 8532301. DOI: 10.1186/s13023-021-02061-3. View

5.
Lopez-Bastida J, Oliva-Moreno J, Linertova R, Serrano-Aguilar P . Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016; 17 Suppl 1:1-5. DOI: 10.1007/s10198-016-0780-7. View